HealthyNCT05986500
The GALAXY-1 Project
A study testing Galactose in people with Healthy, run by University of Aarhus at 1 site in Denmark.
Trial summary
"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for… Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Galactose
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteDenmark
- Study dates
- 12 Feb 2024to 31 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 50-75 years
- Male or post-menopausal female
- BMI 18.5-30 kg/m2
Who cannot join
- Clinically significant heart, lung, kidney, kidney, liver, endocrine or malignant disease based on information obtained during an initial screening visit as well as blood samples
- Blood donation within the last 3 months
- Smoking
- Alcohol- or substance abuse
- Participation in other clinical trials involving ionizing radiation within the last 6 months
- Claustrophobia
- Not being physically able to exercise one leg for one hour
Trial locations and contacts
1 site in 1 country.
Esben Søndergaard, MD, PhD contact
Denmark1 site, 1 recruiting
- Recruiting
Aarhus University Hospital
Aarhus N, Jutland, 8200
Thien V Luong, MD, 31513750 ext. +45, thiluo@clin.au.dk
Esben Søndergaard, MD, PhD, esben.sondergaard@clin.au.dk
About this study
Official title: The GALAXY-1 Project: Galactose - the Ideal Carbohydrate Supplement for Exercise
"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for insulin to maintain normal blood sugar levels. Additionally, galactose oxidation rates during exercise are only 50-60% compared to glucose, primarily due to liver storage and/or the requirement for conversion to glucose in the liver before oxidation. This delay in metabolism can prevent hyperglycemia before exercise and provide extended protection against episodes of hypoglycemia during and after exercise through a moderate and prolonged glycemic response.
The purpose of this experiment is to investigate whether galactose is taken up by skeletal muscles and the heart in response to exercise or hyperinsulinemia. Using non-invasive 18F-FDGal PET, the investigators will examine this in a randomized controlled study design. The results could contribute to updating dietary recommendations, particularly for individuals with type 1 diabetes who struggle to maintain normal blood sugar levels during and after exercise."
Read the detailed description
It is generally accepted that saccharides have to be converted into glucose before they can be oxidized and used to produce energy. As a result, non-glucose saccharides affect blood glucose levels differently than glucose. For example, the saccharide fructose requires hepatic conversion to glucose, causing more constant blood sugar levels and less risk of both glucose excursions and hypoglycemia during exercise. However, metabolization of fructose increases the risk of developing nonalcoholic fatty liver disease due to the stimulation of de novo lipogenesis and blocking of β-fatty acid oxidation. Consequently, a different carbohydrate source with the same glycemic profile as fructose but without the undesirable hepatic effects would be preferable. Galactose is the third of the three quantitively important dietary monosaccharides in a regular Western diet. Lactose (disaccharide of galactose and glucose) from dairy products is the primary source of dietary galactose, but galactose is also found in other food sources such as fruits and vegetables. While the impact of glucose and fructose on human metabolism has been extensively studied, there is limited knowledge of the effects of galactose as a nutritional supplement during or before exercise, and it is also unknown whether it can have clinical applications.
Intake of galactose or lactose instead of glucose prior to exercise may be advantageous, particularly for individuals with diabetes, since it lowers the insulin requirement to maintain euglycemia. Furthermore, galactose oxidation rates during exercise are only 50-60% compared to glucose, presumably due to hepatic storage and/or a requirement for conversion to glucose in the liver before oxidation. This delay in end-point metabolism could prevent hyperglycemia prior to exercise and at the same time provide prolonged protection from hypoglycemia during and after exercise via the prolonged and moderated glycemic response. In line with this, a recent study from the investigators' collaborator Gareth Wallis's group showed that lactose ingestion in relation to exercise increased fat oxidation and lowered carbohydrate oxidation compared to sucrose ingestion. Accordingly, ingestion of the lactose component - galactose - instead of regular glucose-containing carbohydrates is an intriguing option if blood glucose excursions are to be avoided. However, it is still unclear whether the beneficial metabolic effects of galactose are all caused by the hepatic delay in conversion to glucose or if galactose is also used directly by skeletal muscle as a source of energy. To address this, the investigators recently performed positron emission tomography (PET) pilot studies in two pigs using the galactose analogue 18F-FDGal to measure insulin-stimulated skeletal and cardiac muscle galactose uptake. Although muscle galactose uptake was clearly less than for glucose, it was evident that some uptake can be stimulated by insulin, particularly in the heart. These preliminary data question the current perception that galactose requires conversion to glucose in the liver before it can be utilized as a source of energy. However, studies in anesthetized pigs obviously cannot determine whether a similar direct muscle uptake of galactose can be stimulated by exercise per se, as is the case for glucose.
Purpose:
The purpose of this experiment is to investigate whether galactose is: 1) taken up by skeletal muscle and extra-hepatic organs, 2) if galactose uptake is affected by prior high intensity exercise with the purpose of depleting glycogen in the working skeletal muscle, and 3) if and to what extent insulin stimulates galactose uptake.
Methods:
Eight healthy participants will be studied twice in randomized order with 18F-FDGal PET scans during saline infusion (study day 1), and during a hyperinsulinemic-euglycemic clamp (study day 2). To stimulate galactose uptake in the femoral skeletal muscles, each participant will perform a 60-minute one-legged exercise prior to the PET scan. The non-exercised leg will serve as a control to quantify exercise-stimulated galactose uptake (Figure 2). During each study day, participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min) to mimic concentrations of galactose similar to what can be achieved after galactose ingestion (1-2 mmol/L) (10). This design allows the investigators to quantify both the independent and combined effects of insulin and exercise on galactose uptake in skeletal muscle.
Volunteers:
Inclusion criteria:
- Age 50-75 years
- Males or post-menopausal females
- BMI 18.5-30 kg/m2
Exclusion criteria:
- Clinically significant heart, lung, kidney, liver, endocrine, or malignant disease based on information obtained during an initial screening visit as well as blood samples
- Blood donation within the last 3 months
- Smoking
- Alcohol- or substance abuse
- Participation in other clinical trials involving ionizing radiation within the last 6 months
- Claustrophobia
- Not being physically able to exercise one leg for one hour
- Conditions
- Healthy
- Being tested
- Galactose, No intervention
- Keywords
- Galactose, Exercise, PET, Insulin
- Medical subject headings
- Motor Activity, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GalactoseOther
The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)
No interventionOther
The participants will receive a saline infusion
| Study group | Role | What they receive |
|---|---|---|
| Galactose | Experimental | The participants will receive a galactose infusion Receives: Other: Galactose |
| Saline | Experimental | The participants will receive a saline infusion Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Galactose uptake in skeletal muscle
Skeletal muscle galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)
Measured: Measurements will be made on each of the two study days
Secondary outcomes (4)
Cardiac galactose uptake
Cardiac galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)
Measured: Measurements will be made on each of the two study days
Hepatic galactose uptake
Hepatic galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)
Measured: Measurements will be made on each of the two study days
Plasma glucose levels
Measured in blood samples
Measured: Measurements will be made on a screening day and during each of the two study days
Skeletal muscle arterio-venous galactose balance
Differences in arterio-venous galactose concentrations taken through catheters in both vv. famoralis and a. radialis
Measured: Measurements will be mader during each of the two study days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2023
- Study start12 Feb 2024
- Primary completion1 Nov 2024 (estimated)
- Study completion31 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University of AarhusThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 8 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05986500
- Sponsor's protocol ID
- 1-10-72-49-23
- Status last verified
- Aug 2023
- First submitted
- 3 Aug 2023
- Last updated
- 23 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The GALAXY-1 Project: Galactose - the Ideal Carbohydrate Supplement for Exercise
- ClinicalTrials.gov ID
- NCT05986500
- Acronym / sponsor ID
- 1-10-72-49-23
- Conditions
- Healthy
- Keywords
- Galactose, Exercise, PET, Insulin
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 8 participants (estimated)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Study start
- 12 Feb 2024 (actual)
- Primary completion
- 1 Nov 2024 (estimated)
- Study completion
- 31 May 2025 (estimated)
- First posted
- 14 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for insulin to maintain normal blood sugar levels. Additionally, galactose oxidation rates during exercise are only 50-60% compared to glucose, primarily due to liver storage and/or the requirement for conversion to glucose in the liver before oxidation. This delay in metabolism can prevent hyperglycemia before exercise and provide extended protection against episodes of hypoglycemia during and after exercise through a moderate and prolonged glycemic response.
The purpose of this experiment is to investigate whether galactose is taken up by skeletal muscles and the heart in response to exercise or hyperinsulinemia. Using non-invasive 18F-FDGal PET, the investigators will examine this in a randomized controlled study design. The results could contribute to updating dietary recommendations, particularly for individuals with type 1 diabetes who struggle to maintain normal blood sugar levels during and after exercise."
Detailed description
It is generally accepted that saccharides have to be converted into glucose before they can be oxidized and used to produce energy. As a result, non-glucose saccharides affect blood glucose levels differently than glucose. For example, the saccharide fructose requires hepatic conversion to glucose, causing more constant blood sugar levels and less risk of both glucose excursions and hypoglycemia during exercise. However, metabolization of fructose increases the risk of developing nonalcoholic fatty liver disease due to the stimulation of de novo lipogenesis and blocking of β-fatty acid oxidation. Consequently, a different carbohydrate source with the same glycemic profile as fructose but without the undesirable hepatic effects would be preferable. Galactose is the third of the three quantitively important dietary monosaccharides in a regular Western diet. Lactose (disaccharide of galactose and glucose) from dairy products is the primary source of dietary galactose, but galactose is also found in other food sources such as fruits and vegetables. While the impact of glucose and fructose on human metabolism has been extensively studied, there is limited knowledge of the effects of galactose as a nutritional supplement during or before exercise, and it is also unknown whether it can have clinical applications.
Intake of galactose or lactose instead of glucose prior to exercise may be advantageous, particularly for individuals with diabetes, since it lowers the insulin requirement to maintain euglycemia. Furthermore, galactose oxidation rates during exercise are only 50-60% compared to glucose, presumably due to hepatic storage and/or a requirement for conversion to glucose in the liver before oxidation. This delay in end-point metabolism could prevent hyperglycemia prior to exercise and at the same time provide prolonged protection from hypoglycemia during and after exercise via the prolonged and moderated glycemic response. In line with this, a recent study from the investigators' collaborator Gareth Wallis's group showed that lactose ingestion in relation to exercise increased fat oxidation and lowered carbohydrate oxidation compared to sucrose ingestion. Accordingly, ingestion of the lactose component - galactose - instead of regular glucose-containing carbohydrates is an intriguing option if blood glucose excursions are to be avoided. However, it is still unclear whether the beneficial metabolic effects of galactose are all caused by the hepatic delay in conversion to glucose or if galactose is also used directly by skeletal muscle as a source of energy. To address this, the investigators recently performed positron emission tomography (PET) pilot studies in two pigs using the galactose analogue 18F-FDGal to measure insulin-stimulated skeletal and cardiac muscle galactose uptake. Although muscle galactose uptake was clearly less than for glucose, it was evident that some uptake can be stimulated by insulin, particularly in the heart. These preliminary data question the current perception that galactose requires conversion to glucose in the liver before it can be utilized as a source of energy. However, studies in anesthetized pigs obviously cannot determine whether a similar direct muscle uptake of galactose can be stimulated by exercise per se, as is the case for glucose.
Purpose:
The purpose of this experiment is to investigate whether galactose is: 1) taken up by skeletal muscle and extra-hepatic organs, 2) if galactose uptake is affected by prior high intensity exercise with the purpose of depleting glycogen in the working skeletal muscle, and 3) if and to what extent insulin stimulates galactose uptake.
Methods:
Eight healthy participants will be studied twice in randomized order with 18F-FDGal PET scans during saline infusion (study day 1), and during a hyperinsulinemic-euglycemic clamp (study day 2). To stimulate galactose uptake in the femoral skeletal muscles, each participant will perform a 60-minute one-legged exercise prior to the PET scan. The non-exercised leg will serve as a control to quantify exercise-stimulated galactose uptake (Figure 2). During each study day, participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min) to mimic concentrations of galactose similar to what can be achieved after galactose ingestion (1-2 mmol/L) (10). This design allows the investigators to quantify both the independent and combined effects of insulin and exercise on galactose uptake in skeletal muscle.
Volunteers:
Inclusion criteria:
- Age 50-75 years
- Males or post-menopausal females
- BMI 18.5-30 kg/m2
Exclusion criteria:
- Clinically significant heart, lung, kidney, liver, endocrine, or malignant disease based on information obtained during an initial screening visit as well as blood samples
- Blood donation within the last 3 months
- Smoking
- Alcohol- or substance abuse
- Participation in other clinical trials involving ionizing radiation within the last 6 months
- Claustrophobia
- Not being physically able to exercise one leg for one hour
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Galactose | Experimental | Other: GalactoseThe participants will receive a galactose infusion |
| Saline | Experimental | Other: No interventionThe participants will receive a saline infusion |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 50-75 years
- Male or post-menopausal female
- BMI 18.5-30 kg/m2
Key exclusion criteria (7 listed)
- Clinically significant heart, lung, kidney, kidney, liver, endocrine or malignant disease based on information obtained during an initial screening visit as well as blood samples
- Blood donation within the last 3 months
- Smoking
- Alcohol- or substance abuse
- Participation in other clinical trials involving ionizing radiation within the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GalactoseThe participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min) | Other | Galactose |
| No interventionThe participants will receive a saline infusion | Other | Saline |
Primary outcome
Galactose uptake in skeletal muscle
Time frame: Measurements will be made on each of the two study days
Skeletal muscle galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)
4 secondary outcomes
Cardiac galactose uptake
Time frame: Measurements will be made on each of the two study days
Hepatic galactose uptake
Time frame: Measurements will be made on each of the two study days
Plasma glucose levels
Time frame: Measurements will be made on a screening day and during each of the two study days
Skeletal muscle arterio-venous galactose balance
Time frame: Measurements will be mader during each of the two study days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Esben Søndergaard, MD, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Galactose in people with Healthy, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Thien V Luong, MD (+4531513750, thiluo@clin.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Galactose uptake in skeletal muscle (time frame: Measurements will be made on each of the two study days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.